Replies to post #3554 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: rFVIIa for trauma

>To me this study is not a big deal.<

I agree that it’s a minor study; after all, rFVIIa was used in both arms and only the scheduling of its use was a variable.

>A significant study would be morbidity and mortality with factor 7 versus no factor 7 infusion in trauma....or has it been done already?<

One such study with 280 patients is reported on here: #msg-13925693. It showed a survival trend favoring the rFVIIa arm and a statsig reduction in bleeding relative to the control arm in patients with blunt trauma, specifically. Regards, Dew